# Bioanalytical Systems Inc.

Bioanalytical Systems Inc. (www.basinc.com), 2701 Kent Ave., West Lafayette, 47906, is a provider of contract-research services to the pharmaceutical industry. In the fiscal year that ended Sept. 30, 2012, Bioanalytical lost $6.3 million, or 89 cents per share, on revenue of $28.2 million. In the same period a year earlier, the company lost $3.7 million, or 66 cents per share, on revenue of $33.1 million. Bioanalytical Systems shares trade on NASDAQ under the ticker BASI. Information for Proxy Corner was taken from Yahoo Finance and the company's proxy statement dated Feb. 7, 2013.

| VALUE | 2/15/13 | 2/10/12 |
|---|---|---|
| Shares of common stock outstanding | 7.7 million | 7.0 million |
| Market value of one common share | $1.60 | $1.22 |
| Market value of common stock | $12.3 million | $8.5 million |

## NOTEWORTHY CONTROL

**Peter and Candice Kissinger**
**Number of common shares:** 1,275,967
**Percentage of common shares:** 16.7

**Seth Hamot**
**Number of common shares:** 837,296
**Percentage of common shares:** 10.9

## EXECUTIVE COMPENSATION

| | Total '12 compensation | Salary / Bonus | Stock and option grants (1) | All other pay (2) | % change (3) |
|---|---|---|---|---|---|
| **Jacqueline Lemke (4)** interim president, CEO | $272,657 | $101,890 / $31,267 | $139,500 | $0 | NA |
| **Lori Payne** vice president | $200,119 | $150,467 / $10,000 | $22,320 | $17,332 | NA |
| **John Devine Jr.** vice president | $145,000 | $145,000 / $0 | $0 | $0 | NA |
| **Anthony Chilton (5)** president, CEO | $425,987 | $194,547 / $0 | $27,900 | $203,540 | 1.4% |
| **Michael Cox (6)** chief financial officer | $281,771 | $82,500 / $0 | $0 | $199,271 | 52.3% |

*(1) Grant date fair value of stock and options awards, as calculated in company's proxy statement in its grant of plan-based awards table.*

*(2) Includes non-equity incentive plan compensation, above-market or preferential earnings on deferred compensation and all other annual compensation.*

*(3) Percentage increase or decrease in executive's total compensation vs. previous year.*

*(4) Became interim president and CEO on July 5, 2012. Appointed permanent president and CEO on Feb. 7, 2013.*

*(5) Resigned as president and CEO on July 5, 2012.*

*(6) Left company on March 31, 2012*

## NOTEWORTHY CONTROL

**John Landis, 59**
**Occupation:** chairman of company, retired vice president of Schering-Plough Corp.
**Number of common shares:** 30,000

**David Omachinski, 59**
**Occupation:** executive management consultant
**Number of common shares:** 22,500

**Richard A. Johnson, 67**
**Occupation:** executive scientific consultant
**Number of common shares:** 10,000

**Larry Boulet, 66**
**Occupation:** retired PricewaterhouseCoopers partner
**Number of common shares:** 23,750

**A. Charlene Sullivan, 63**
**Occupation:** associate professor of management in the School of Management and Krannert Graduate School of Management at Purdue University
**Number of common shares:** 12,500

**David Crabb, 59**
**Occupation:** chairman of the Indiana University Department of Medicine
**Number of common shares:** 11,300

*All officers and directors as a group (nine people) control 152,650 shares, or 2.0 percent of the total. The prior year, nine insiders controlled 1,127,971 shares, or 19.8 percent, of the total.*